VISCIDO, ANGELO
 Distribuzione geografica
Continente #
NA - Nord America 8.930
EU - Europa 4.201
AS - Asia 4.189
SA - Sud America 566
AF - Africa 50
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 4
Totale 17.949
Nazione #
US - Stati Uniti d'America 8.786
SG - Singapore 1.845
RU - Federazione Russa 1.003
IE - Irlanda 982
CN - Cina 866
BR - Brasile 475
DE - Germania 465
IT - Italia 429
HK - Hong Kong 428
TR - Turchia 400
VN - Vietnam 355
SE - Svezia 255
GB - Regno Unito 252
UA - Ucraina 227
FR - Francia 187
FI - Finlandia 180
CA - Canada 81
IN - India 69
BD - Bangladesh 45
AR - Argentina 44
CZ - Repubblica Ceca 44
JP - Giappone 44
MX - Messico 36
NL - Olanda 34
BE - Belgio 32
PL - Polonia 32
ID - Indonesia 24
ES - Italia 23
IQ - Iraq 22
ZA - Sudafrica 20
AT - Austria 12
CO - Colombia 12
LT - Lituania 11
PH - Filippine 11
EC - Ecuador 8
MA - Marocco 8
SA - Arabia Saudita 8
VE - Venezuela 8
JM - Giamaica 7
MY - Malesia 7
PE - Perù 7
RO - Romania 7
UZ - Uzbekistan 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
JO - Giordania 6
KR - Corea 6
BG - Bulgaria 5
IL - Israele 5
CH - Svizzera 4
CL - Cile 4
CR - Costa Rica 4
EU - Europa 4
LB - Libano 4
PK - Pakistan 4
PT - Portogallo 4
TH - Thailandia 4
TN - Tunisia 4
EG - Egitto 3
GE - Georgia 3
HN - Honduras 3
NP - Nepal 3
PR - Porto Rico 3
PY - Paraguay 3
AM - Armenia 2
AZ - Azerbaigian 2
BS - Bahamas 2
CD - Congo 2
CG - Congo 2
GT - Guatemala 2
HU - Ungheria 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MK - Macedonia 2
NZ - Nuova Zelanda 2
OM - Oman 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BF - Burkina Faso 1
BM - Bermuda 1
BO - Bolivia 1
BT - Bhutan 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DM - Dominica 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GH - Ghana 1
GY - Guiana 1
IR - Iran 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
MW - Malawi 1
Totale 17.939
Città #
Singapore 999
Chandler 979
Dublin 972
Jacksonville 943
San Jose 857
Dallas 850
Ashburn 741
Hong Kong 423
Santa Clara 407
Council Bluffs 340
Boardman 321
The Dalles 225
Izmir 197
New York 193
Nanjing 159
Beijing 154
San Mateo 151
Lawrence 149
Princeton 149
Wilmington 143
Moscow 140
Ho Chi Minh City 121
Ann Arbor 114
Los Angeles 109
Munich 101
Hanoi 78
Lauterbourg 78
Dearborn 76
Milan 70
L'aquila 62
São Paulo 61
Bremen 50
Hefei 46
Helsinki 42
Woodbridge 42
Seattle 41
Columbus 40
Des Moines 39
Brno 38
Nanchang 37
Rome 37
Shenyang 37
Frankfurt am Main 36
Tokyo 35
Turku 33
Brussels 32
Montreal 32
Tianjin 32
Verona 32
Kunming 31
Orem 31
Warsaw 30
London 29
Berlin 28
Phoenix 28
Shanghai 28
Jinan 25
Norwalk 25
Lappeenranta 22
Poplar 22
Chennai 21
Amsterdam 20
Boston 20
Brooklyn 20
Stockholm 20
Mumbai 19
Rio de Janeiro 19
Toronto 19
Jiaxing 18
Zhengzhou 18
Haiphong 16
Hebei 16
Belo Horizonte 15
Falkenstein 15
San Francisco 15
Atlanta 14
Brasília 14
Chicago 14
L’Aquila 14
Manchester 14
Mexico City 14
Pescara 14
Denver 13
Mountain View 13
Changsha 12
Dong Ket 12
Fairfield 11
Ankara 10
Biên Hòa 10
Florence 10
Jakarta 10
Ningbo 10
Da Nang 9
Fremont 9
Guangzhou 9
Hangzhou 9
Johannesburg 9
Baghdad 8
Changchun 8
Houston 8
Totale 11.891
Nome #
Efficacia di un nuovo preparato di olio di pesce sulla recidiva del Morbo di Crohn. Giornale di Gastroenterologia 1996;1:158-162 336
Effectiveness of Vitamin D Supplementation on Disease Course in Inflammatory Bowel Disease Patients: Systematic Review With Meta-Analysis 305
Non-steroidal anti-inflammatory drugs and acetylsalicylic acid increase the risk of complications of diverticular disease: a meta-analysis of case–control and cohort studies 287
The Relationship Between Nutritional Status, Micronutrient Deficiency, and Disease Activity in IBD Patients: A Multicenter Cross-Sectional Study 251
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 185
Subtypes of chronic gastritis in patients with celiac disease before and after gluten-free diet 179
Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms 169
Histological healing in ulcerative colitis with mesalazine and its prognostic role 161
Subtypes of chronic gastritis in patients with coeliac disease before and after gluten-free diet 158
Mesalazine treatment in organotypic culture of celiac patients: Comparative study with gluten free diet 157
The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine 156
Association between colonic diverticula and colorectal polyps and cancer 151
Lymphocytic gastritis is present in Celiac Disease and improves after gluten-free diet. 148
Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet 148
Risk of colonoscopic post-polypectomy bleeding in patients on single antiplatelet therapy: systematic review with meta-analysis 148
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 145
GI distension in severe ulcerative colitis 144
Association between colorectal polyps and colonic diverticulosis 144
Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. 142
Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) 138
Can Nrf2 modulate the development of intestinal fibrosis and cancer in inflammatory bowel disease? 135
Sleep disorders related to nutrition and digestive diseases: A neglected clinical condition 135
Association between corrected QT interval and C-reactive protein in patients with inflammatory bowel diseases 134
Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? 134
Persistent iron deficiency anemia in patients with celiac disease despite a gluten-free diet 133
Pericarditis after sars‐cov‐2 infection: Another pebble in the mosaic of long covid? 132
SpA plus IBD or IBD plus SpA: Does commutative property apply? 131
Inflammatory bowel disease: New insights into the interplay between environmental factors and pparγ 130
Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn's Disease: Do They Still Have a Potential Clinical Role? 130
Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology 130
The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients 129
Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. 129
Are volatile organic compounds accurate markers in the assessment of colorectal cancer and inflammatory bowel diseases? A review 129
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis 127
Is fecal calprotectin an accurate marker in the management of Crohn's disease? 126
Colite acuta dopo colonscopia. Giornale di Gastroenterologia 1997; 2: 88-93 125
The usefulness of serum vitamin D levels in the assessment of IBD activity and response to biologics 125
Site and duration of abdominal pain discriminate symptomatic uncomplicated diverticular disease from previous diverticulitis patients 123
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. 123
Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea 123
Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn's disease: state of the art and review of the literature 123
Is mesalazine treatment effective in the prevention of diverticulitis? A review 121
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 121
Current management of severe ulcerative colitis. 121
Anastomotic configuration and mucosal 5-aminosalicylic acid (5-ASA) concentrations in patients with Crohn's Disease: a GISC study 120
Mucosal healing: Mayo 0 vs 1 after 3 years. 120
Duodenal lymphocytosis in functional dyspepsia 120
Celiac disease, gluten-free diet, and metabolic and liver disorders 120
Multicenter validation of the DETAIL questionnaire for the screening of spondyloarthritis in patients with inflammatory bowel diseases 120
Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis 119
Association of colonic diverticula with colorectal adenomas and cancer 119
Inflammatory Bowel Disease in the Post-STRIDE II Era: Epidemiology and Long-Term Clinical Outcomes from a Population-Based Study 117
Survival and causes of death in Italian patients with ulcerative colitis. A GISC nation-wide study. 117
Persistence of anemia in patients with Celiac disease despite a gluten free diet: a retrospective study 116
Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. 116
Nanotechnology in the treatment of inflammatory bowel diseases. 116
Vitamin D in Inflammatory Bowel Diseases. Mechanisms of Action and Therapeutic Implications 116
Immunoglobulin G4-Related Disease of the Intestine: A Clinicopathological Entity to Be Considered 115
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey 115
5-ASA enemas increase mucosal availability of mesalamine up to splenic flexure. 112
L’intestino nei pazienti critici. La barriera mucosa intestinale e le sue alterazioni (prima parte). Giornale di Gastroenterologia 1998; 3: 70-103 112
Immune-mediated inflammatory diseases after anti-SARS-CoV-2 vaccines: new diagnoses and disease flares 111
Acute colitis following colonoscopy 111
Safe use of infliximab for the treatment of fistulizing Crohn’s disease during pregnancy within 3 months of conception. 111
NK activity and antibody-dependent cellular citotoxicity (ADCC) in inflammatory bowel disease(IBD) 110
In favour of prophylactic treatment for post-operative recurrence in Crohn's disease. 110
Prognostic factors for post-operative recurrence of Crohn's disease 110
Dietary factors modulating colorectal carcinogenesis 110
Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease 109
MRI EVALUATION OF CROHN DISEASE OF THE SMALL AND LARGE BOWEL USING NEGATIVE SUPERPARAMAGNETIC CONTRAST AGENT 109
Serum transglutaminase antibodies do not always detect the persistent villous atrophy in patients with celiac disease on a gluten-free diet 109
Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment 108
The role on endoscopy in alcohol-related diseases 107
Acute colitis following endoscopy: an outbreak of three cases 106
Unmet medical needs in the management of ulcerative colitis: Results of an Italian delphi consensus 106
The long-term effect on surgery-free survival of biological compared to conventional therapy in Crohn's disease in real world-data: a retrospective study 106
Attività NK ed ADCC in pazienti con malattie infiammatorie intestinali (IBD). 105
Italian Group for the Study of the Colon and Rectum: Survival and causes of death in Italian patients with ulcerative colitis. A GISC nationwide study 104
Colonic mucosal concentration of 5-ASA in ulcerative colitis. 104
Small intestine contrast ultrasonography: An alternative to radiology in the assessment of small bowel disease 104
Quinidine-induced colitis. Report of three cases. 103
Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis. 103
A new technique of magnetic resonance imaging (MRI) in the management of patients with Crohn's disease. 102
An unusual treatment for a colonic polyp. 101
Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases. 101
Recidive stenosanti ricorrenti nel morbo di Crohn. Giornale di Gastroenterologia, 1999, 4: 150-155 101
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study 100
Value of T2-weighted fat suppressed and non suppressed sequences after oral administration of a superparamagnetic contrast agent in the assessmento of Crohn's disease activity 99
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 99
Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations 98
Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. 98
Linfociti circolanti gamma-delta in corso di malattie infiammatorie intestinali. 98
Evaluation of Crohn disease activity with magnetic resonance imaging 98
Il 5-ASA (ASACOL) previene le recidive post-operatorie del morbo di crohn (MC): risultati dello studio GISC a tre anni di follow-up. 97
Two mesalazine regimens in the prevention of postoperative recurrence of Crohn's disease: A pragmatic double blind randomised controlled trial . Aliment Pharmacol Ther 2003;17:517-523 97
Two mesalazine regimens in the prevention of postoperative recurrence of Crohn's disease: A double blind randomised clinical trial. AGISC study. 96
5-ASA enemas increase mucosal availability of mesalamine up to splenic flexure. 96
Wegener's granulomatosis and retroperitoneal fibrosis: A case report and review of the literature 96
Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology 95
Gastrointestinal distension in severe ulcerative colitis 95
Totale 12.734
Categoria #
all - tutte 76.776
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 76.776


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022799 34 60 94 39 32 27 12 58 43 32 68 300
2022/20232.841 216 159 44 293 257 301 0 204 1.233 16 84 34
2023/2024990 98 28 29 91 47 167 30 285 4 39 51 121
2024/20253.074 69 50 288 98 298 317 382 265 686 180 222 219
2025/20266.496 253 640 602 759 627 452 1.021 217 582 816 429 98
2026/2027453 453 0 0 0 0 0 0 0 0 0 0 0
Totale 18.192